10x Genomics (NASDAQ:TXG – Get Free Report) and Hims & Hers Health (NYSE:HIMS – Get Free Report) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.
Profitability
This table compares 10x Genomics and Hims & Hers Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 10x Genomics | -6.77% | -6.89% | -5.34% |
| Hims & Hers Health | 5.47% | 22.48% | 7.02% |
Analyst Ratings
This is a breakdown of recent ratings and price targets for 10x Genomics and Hims & Hers Health, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 10x Genomics | 3 | 9 | 4 | 0 | 2.06 |
| Hims & Hers Health | 1 | 13 | 3 | 0 | 2.12 |
Risk & Volatility
10x Genomics has a beta of 2.2, meaning that its share price is 120% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 2.55, meaning that its share price is 155% more volatile than the S&P 500.
Valuation and Earnings
This table compares 10x Genomics and Hims & Hers Health”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 10x Genomics | $642.82 million | 3.65 | -$43.54 million | ($0.35) | -52.51 |
| Hims & Hers Health | $2.35 billion | 2.34 | $128.37 million | $0.51 | 47.32 |
Hims & Hers Health has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 9.4% of 10x Genomics shares are owned by company insiders. Comparatively, 13.7% of Hims & Hers Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Hims & Hers Health beats 10x Genomics on 11 of the 14 factors compared between the two stocks.
About 10x Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
About Hims & Hers Health
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
